[Recent therapeutic strategy for follicular lymphoma].
Ogura
Michinori
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000069461:Bendamustine Hydrochloride; D004334:Drug Administration Schedule; D015195:Drug Design; D004359:Drug Therapy, Combination; D005438:Fludrocortisone / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D008224:Lymphoma, Follicular / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D016499:Radioimmunotherapy; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D000069461:Bendamustine Hydrochloride; C119496:tositumomab I-131; D005438:Fludrocortisone